Global Psychedelic Drugs Market
Global Psychedelic Drugs Market

Psychedelic Drugs Comprehensive Study by Application (Major Depressive Disorder, Resistant Depression, Panic Disorder, Post-traumatic Stress Disorder, Opiate Addiction, Others), Drug Type (Lysergic Acid Diethylamide (LSD), 3,4-MethylEnedioxyMethamphetamine (Ecstasy), Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Ketamine, Ayahuasca, Salvia, Psilocybin, Others), Route of Administration (Oral, Injectable, Inhalation), Distribution Channel (Direct Retailers, Online Pharmacies, Others), End User (Hospitals, Homecare, Specialty Clinics, Others)

Psychedelic Drugs Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Aug 2020 Edition 212 Pages 214 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Psychedelic Drugs Market Overview:
Psychedelic Drugs, also known as psychedelics include both classic hallucinogens and dissociative drugs. These drugs are used in the treatment of the major depressive disorder, treatment-resistant depression, panic disorder, and promoting spiritual experiences. These drugs are used experimentally to mimic psychosis and to exert mind control. The increasing scientific researches of psychedelics drugs is expected to boost the market growth in the forecast period. Some of the key players profiled in the study are COMPASS (United Kingdom), The Emmes Company, LLC (United States), Klarisana (United Kingdom), AstraZeneca PLC (United Kingdom), F. Hoffmann-La Roche AG (Switzerland), Dr. Reddy’s Laboratories Ltd (India), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc (United States), Mylan N.V. (United States), Merck & Co., Inc (United States), Alkermes (Ireland), Allergan plc (Ireland) and H. Lundbeck A/S (Denmark).

On the basis of geography, the market of Psychedelic Drugs has been segmented into . If we see Market by Drug Type, the sub-segment i.e. Lysergic Acid Diethylamide (LSD) will boost the Psychedelic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Psychedelic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Direct Retailers will boost the Psychedelic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Psychedelic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Occurrence of Depression
  • Treatment for Psychedelic Drugs Dependency


Restraints
  • Preference of Non-Therapeutics Therapies

Opportunities
  • Changing Life Style and Demand for Enhanced Life Quality
  • Growing Acceptance of Psychedelic Drugs for Treating Depression

Challenges
  • Poor Efficacy and Safety Profile Of Existing Intervention


Major Market Developments:


In September 2019, Johns Hopkins Medicine launched a new research center named Center for Psychedelic and Consciousness Research, with USD 17 million with aim to offer “psychedelic medicine”.

Target Audience:
New Entrants/Investors, Analysts and Strategic Business Planners, Psychedelic Drugs Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Psychedelic Drugs market on the basis of product [] , application [Major Depressive Disorder, Resistant Depression, Panic Disorder, Post-traumatic Stress Disorder, Opiate Addiction and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Psychedelic Drugs market with respect to major geographies, namely,
• To strategically profile the key players and analyzing their market shares and core competencies in the Psychedelic Drugs industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Psychedelic Drugs market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Application
  • Major Depressive Disorder
  • Resistant Depression
  • Panic Disorder
  • Post-traumatic Stress Disorder
  • Opiate Addiction
  • Others
By Drug Type
  • Lysergic Acid Diethylamide (LSD)
  • 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
  • Phencyclidine
  • Gamma Hydroxybutyric Acid (GHB)
  • Ketamine
  • Ayahuasca
  • Salvia
  • Psilocybin
  • Others

By Route of Administration
  • Oral
  • Injectable
  • Inhalation

By Distribution Channel
  • Direct Retailers
  • Online Pharmacies
  • Others

By End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Increasing Occurrence of Depression
        • 3.2.2. Treatment for Psychedelic Drugs Dependency
      • 3.3. Market Challenges
        • 3.3.1. Poor Efficacy and Safety Profile Of Existing Intervention
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Psychedelic Drugs, by Application, Drug Type, Route of Administration, Distribution Channel and End User (value, volume and price ) (2014-2019)
      • 5.1. Introduction
      • 5.2. Global Psychedelic Drugs (Value)
        • 5.2.1. Global Psychedelic Drugs by: Application (Value)
          • 5.2.1.1. Major Depressive Disorder
          • 5.2.1.2. Resistant Depression
          • 5.2.1.3. Panic Disorder
          • 5.2.1.4. Post-traumatic Stress Disorder
          • 5.2.1.5. Opiate Addiction
          • 5.2.1.6. Others
        • 5.2.2. Global Psychedelic Drugs by: Drug Type (Value)
          • 5.2.2.1. Lysergic Acid Diethylamide (LSD)
          • 5.2.2.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
          • 5.2.2.3. Phencyclidine
          • 5.2.2.4. Gamma Hydroxybutyric Acid (GHB)
          • 5.2.2.5. Ketamine
          • 5.2.2.6. Ayahuasca
          • 5.2.2.7. Salvia
          • 5.2.2.8. Psilocybin
          • 5.2.2.9. Others
        • 5.2.3. Global Psychedelic Drugs by: Route of Administration (Value)
          • 5.2.3.1. Oral
          • 5.2.3.2. Injectable
          • 5.2.3.3. Inhalation
        • 5.2.4. Global Psychedelic Drugs by: Distribution Channel (Value)
          • 5.2.4.1. Direct Retailers
          • 5.2.4.2. Online Pharmacies
          • 5.2.4.3. Others
        • 5.2.5. Global Psychedelic Drugs by: End User (Value)
          • 5.2.5.1. Hospitals
          • 5.2.5.2. Homecare
          • 5.2.5.3. Specialty Clinics
          • 5.2.5.4. Others
      • 5.3. Global Psychedelic Drugs (Volume)
        • 5.3.1. Global Psychedelic Drugs by: Application (Volume)
          • 5.3.1.1. Major Depressive Disorder
          • 5.3.1.2. Resistant Depression
          • 5.3.1.3. Panic Disorder
          • 5.3.1.4. Post-traumatic Stress Disorder
          • 5.3.1.5. Opiate Addiction
          • 5.3.1.6. Others
        • 5.3.2. Global Psychedelic Drugs by: Drug Type (Volume)
          • 5.3.2.1. Lysergic Acid Diethylamide (LSD)
          • 5.3.2.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
          • 5.3.2.3. Phencyclidine
          • 5.3.2.4. Gamma Hydroxybutyric Acid (GHB)
          • 5.3.2.5. Ketamine
          • 5.3.2.6. Ayahuasca
          • 5.3.2.7. Salvia
          • 5.3.2.8. Psilocybin
          • 5.3.2.9. Others
        • 5.3.3. Global Psychedelic Drugs by: Route of Administration (Volume)
          • 5.3.3.1. Oral
          • 5.3.3.2. Injectable
          • 5.3.3.3. Inhalation
        • 5.3.4. Global Psychedelic Drugs by: Distribution Channel (Volume)
          • 5.3.4.1. Direct Retailers
          • 5.3.4.2. Online Pharmacies
          • 5.3.4.3. Others
        • 5.3.5. Global Psychedelic Drugs by: End User (Volume)
          • 5.3.5.1. Hospitals
          • 5.3.5.2. Homecare
          • 5.3.5.3. Specialty Clinics
          • 5.3.5.4. Others
      • 5.4. Global Psychedelic Drugs (Price)
    • 6. Psychedelic Drugs: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2019)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. COMPASS (United Kingdom)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. The Emmes Company, LLC (United States)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. Klarisana (United Kingdom)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. AstraZeneca PLC (United Kingdom)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. F. Hoffmann-La Roche AG (Switzerland)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. Dr. Reddy’s Laboratories Ltd (India)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Takeda Pharmaceutical Company Limited (Japan)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Pfizer Inc (United States)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. Mylan N.V. (United States)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. Merck & Co., Inc (United States)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
        • 6.4.11. Alkermes (Ireland)
          • 6.4.11.1. Business Overview
          • 6.4.11.2. Products/Services Offerings
          • 6.4.11.3. Financial Analysis
          • 6.4.11.4. SWOT Analysis
        • 6.4.12. Allergan plc (Ireland)
          • 6.4.12.1. Business Overview
          • 6.4.12.2. Products/Services Offerings
          • 6.4.12.3. Financial Analysis
          • 6.4.12.4. SWOT Analysis
        • 6.4.13. H. Lundbeck A/S (Denmark)
          • 6.4.13.1. Business Overview
          • 6.4.13.2. Products/Services Offerings
          • 6.4.13.3. Financial Analysis
          • 6.4.13.4. SWOT Analysis
    • 7. Global Psychedelic Drugs Sale, by Application, Drug Type, Route of Administration, Distribution Channel and End User (value, volume and price ) (2020-2025)
      • 7.1. Introduction
      • 7.2. Global Psychedelic Drugs (Value)
        • 7.2.1. Global Psychedelic Drugs by: Application (Value)
          • 7.2.1.1. Major Depressive Disorder
          • 7.2.1.2. Resistant Depression
          • 7.2.1.3. Panic Disorder
          • 7.2.1.4. Post-traumatic Stress Disorder
          • 7.2.1.5. Opiate Addiction
          • 7.2.1.6. Others
        • 7.2.2. Global Psychedelic Drugs by: Drug Type (Value)
          • 7.2.2.1. Lysergic Acid Diethylamide (LSD)
          • 7.2.2.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
          • 7.2.2.3. Phencyclidine
          • 7.2.2.4. Gamma Hydroxybutyric Acid (GHB)
          • 7.2.2.5. Ketamine
          • 7.2.2.6. Ayahuasca
          • 7.2.2.7. Salvia
          • 7.2.2.8. Psilocybin
          • 7.2.2.9. Others
        • 7.2.3. Global Psychedelic Drugs by: Route of Administration (Value)
          • 7.2.3.1. Oral
          • 7.2.3.2. Injectable
          • 7.2.3.3. Inhalation
        • 7.2.4. Global Psychedelic Drugs by: Distribution Channel (Value)
          • 7.2.4.1. Direct Retailers
          • 7.2.4.2. Online Pharmacies
          • 7.2.4.3. Others
        • 7.2.5. Global Psychedelic Drugs by: End User (Value)
          • 7.2.5.1. Hospitals
          • 7.2.5.2. Homecare
          • 7.2.5.3. Specialty Clinics
          • 7.2.5.4. Others
      • 7.3. Global Psychedelic Drugs (Volume)
        • 7.3.1. Global Psychedelic Drugs by: Application (Volume)
          • 7.3.1.1. Major Depressive Disorder
          • 7.3.1.2. Resistant Depression
          • 7.3.1.3. Panic Disorder
          • 7.3.1.4. Post-traumatic Stress Disorder
          • 7.3.1.5. Opiate Addiction
          • 7.3.1.6. Others
        • 7.3.2. Global Psychedelic Drugs by: Drug Type (Volume)
          • 7.3.2.1. Lysergic Acid Diethylamide (LSD)
          • 7.3.2.2. 3,4-MethylEnedioxyMethamphetamine (Ecstasy)
          • 7.3.2.3. Phencyclidine
          • 7.3.2.4. Gamma Hydroxybutyric Acid (GHB)
          • 7.3.2.5. Ketamine
          • 7.3.2.6. Ayahuasca
          • 7.3.2.7. Salvia
          • 7.3.2.8. Psilocybin
          • 7.3.2.9. Others
        • 7.3.3. Global Psychedelic Drugs by: Route of Administration (Volume)
          • 7.3.3.1. Oral
          • 7.3.3.2. Injectable
          • 7.3.3.3. Inhalation
        • 7.3.4. Global Psychedelic Drugs by: Distribution Channel (Volume)
          • 7.3.4.1. Direct Retailers
          • 7.3.4.2. Online Pharmacies
          • 7.3.4.3. Others
        • 7.3.5. Global Psychedelic Drugs by: End User (Volume)
          • 7.3.5.1. Hospitals
          • 7.3.5.2. Homecare
          • 7.3.5.3. Specialty Clinics
          • 7.3.5.4. Others
      • 7.4. Global Psychedelic Drugs (Price)
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Psychedelic Drugs: by Application(USD Million)
    • Table 2. Psychedelic Drugs: by Drug Type(USD Million)
    • Table 3. Psychedelic Drugs: by Route of Administration(USD Million)
    • Table 4. Psychedelic Drugs: by Distribution Channel(USD Million)
    • Table 5. Psychedelic Drugs: by End User(USD Million)
    • Table 6. Psychedelic Drugs Sales: by Application(K Tons)
    • Table 7. Psychedelic Drugs Sales: by Drug Type(K Tons)
    • Table 8. Psychedelic Drugs Sales: by Route of Administration(K Tons)
    • Table 9. Psychedelic Drugs Sales: by Distribution Channel(K Tons)
    • Table 10. Psychedelic Drugs Sales: by End User(K Tons)
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. Company Basic Information, Sales Area and Its Competitors
    • Table 17. Company Basic Information, Sales Area and Its Competitors
    • Table 18. Company Basic Information, Sales Area and Its Competitors
    • Table 19. Company Basic Information, Sales Area and Its Competitors
    • Table 20. Company Basic Information, Sales Area and Its Competitors
    • Table 21. Company Basic Information, Sales Area and Its Competitors
    • Table 22. Company Basic Information, Sales Area and Its Competitors
    • Table 23. Company Basic Information, Sales Area and Its Competitors
    • Table 24. Psychedelic Drugs: by Application(USD Million)
    • Table 25. Psychedelic Drugs: by Drug Type(USD Million)
    • Table 26. Psychedelic Drugs: by Route of Administration(USD Million)
    • Table 27. Psychedelic Drugs: by Distribution Channel(USD Million)
    • Table 28. Psychedelic Drugs: by End User(USD Million)
    • Table 29. Psychedelic Drugs Sales: by Application(K Tons)
    • Table 30. Psychedelic Drugs Sales: by Drug Type(K Tons)
    • Table 31. Psychedelic Drugs Sales: by Route of Administration(K Tons)
    • Table 32. Psychedelic Drugs Sales: by Distribution Channel(K Tons)
    • Table 33. Psychedelic Drugs Sales: by End User(K Tons)
    • Table 34. Research Programs/Design for This Report
    • Table 35. Key Data Information from Secondary Sources
    • Table 36. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Psychedelic Drugs: by Application USD Million (2014-2019)
    • Figure 5. Global Psychedelic Drugs: by Drug Type USD Million (2014-2019)
    • Figure 6. Global Psychedelic Drugs: by Route of Administration USD Million (2014-2019)
    • Figure 7. Global Psychedelic Drugs: by Distribution Channel USD Million (2014-2019)
    • Figure 8. Global Psychedelic Drugs: by End User USD Million (2014-2019)
    • Figure 9. Global Psychedelic Drugs: by Application K Tons (2014-2019)
    • Figure 10. Global Psychedelic Drugs: by Drug Type K Tons (2014-2019)
    • Figure 11. Global Psychedelic Drugs: by Route of Administration K Tons (2014-2019)
    • Figure 12. Global Psychedelic Drugs: by Distribution Channel K Tons (2014-2019)
    • Figure 13. Global Psychedelic Drugs: by End User K Tons (2014-2019)
    • Figure 14. Global Psychedelic Drugs share by Players 2019 (%)
    • Figure 15. Global Psychedelic Drugs share by Players (Top 3) 2019(%)
    • Figure 16. Global Psychedelic Drugs share by Players (Top 5) 2019(%)
    • Figure 17. BCG Matrix for key Companies
    • Figure 18. COMPASS (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 19. COMPASS (United Kingdom) Revenue: by Geography 2019
    • Figure 20. The Emmes Company, LLC (United States) Revenue, Net Income and Gross profit
    • Figure 21. The Emmes Company, LLC (United States) Revenue: by Geography 2019
    • Figure 22. Klarisana (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 23. Klarisana (United Kingdom) Revenue: by Geography 2019
    • Figure 24. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 25. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2019
    • Figure 26. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
    • Figure 27. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2019
    • Figure 28. Dr. Reddy’s Laboratories Ltd (India) Revenue, Net Income and Gross profit
    • Figure 29. Dr. Reddy’s Laboratories Ltd (India) Revenue: by Geography 2019
    • Figure 30. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
    • Figure 31. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2019
    • Figure 32. Pfizer Inc (United States) Revenue, Net Income and Gross profit
    • Figure 33. Pfizer Inc (United States) Revenue: by Geography 2019
    • Figure 34. Mylan N.V. (United States) Revenue, Net Income and Gross profit
    • Figure 35. Mylan N.V. (United States) Revenue: by Geography 2019
    • Figure 36. Merck & Co., Inc (United States) Revenue, Net Income and Gross profit
    • Figure 37. Merck & Co., Inc (United States) Revenue: by Geography 2019
    • Figure 38. Alkermes (Ireland) Revenue, Net Income and Gross profit
    • Figure 39. Alkermes (Ireland) Revenue: by Geography 2019
    • Figure 40. Allergan plc (Ireland) Revenue, Net Income and Gross profit
    • Figure 41. Allergan plc (Ireland) Revenue: by Geography 2019
    • Figure 42. H. Lundbeck A/S (Denmark) Revenue, Net Income and Gross profit
    • Figure 43. H. Lundbeck A/S (Denmark) Revenue: by Geography 2019
    • Figure 44. Global Psychedelic Drugs: by Application USD Million (2020-2025)
    • Figure 45. Global Psychedelic Drugs: by Drug Type USD Million (2020-2025)
    • Figure 46. Global Psychedelic Drugs: by Route of Administration USD Million (2020-2025)
    • Figure 47. Global Psychedelic Drugs: by Distribution Channel USD Million (2020-2025)
    • Figure 48. Global Psychedelic Drugs: by End User USD Million (2020-2025)
    • Figure 49. Global Psychedelic Drugs: by Application K Tons (2020-2025)
    • Figure 50. Global Psychedelic Drugs: by Drug Type K Tons (2020-2025)
    • Figure 51. Global Psychedelic Drugs: by Route of Administration K Tons (2020-2025)
    • Figure 52. Global Psychedelic Drugs: by Distribution Channel K Tons (2020-2025)
    • Figure 53. Global Psychedelic Drugs: by End User K Tons (2020-2025)
    Some of the key companies/manufacturers profiled in the report
    • COMPASS (United Kingdom)
    • The Emmes Company, LLC (United States)
    • Klarisana (United Kingdom)
    • AstraZeneca PLC (United Kingdom)
    • F. Hoffmann-La Roche AG (Switzerland)
    • Dr. Reddy’s Laboratories Ltd (India)
    • Takeda Pharmaceutical Company Limited (Japan)
    • Pfizer Inc (United States)
    • Mylan N.V. (United States)
    • Merck & Co., Inc (United States)
    • Alkermes (Ireland)
    • Allergan plc (Ireland)
    • H. Lundbeck A/S (Denmark)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation